A Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE)

Study acronym: RESOLVE
StatusRecruiting
PhasePhase 4
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study sites: 20 to 22
  2. Trial sites expanded: 14 → 20 locations
    • Eligibility criteria expanded, about 32 words
    • Secondary endpoints: details revised at 2 of 2 entries
  3. Trial sites expanded: 5 → 14 locationsv3
  4. Trial sites expanded: 1 → 5 locations
    • Start date changed from estimate of Jun 2026 to May 20, 2026
    v2
  5. Study First Submitted
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The primary purpose of this study is to evaluate the safety and tolerability of Zunveyl® over 12 weeks of routine clinical use in adults with mild to moderate Alzheimer's disease.
Trial Details
NCT Number NCT07633470
Lead Sponsor Alpha Cognition, Inc
Conditions
(from sponsor)		 Alzheimer Disease
Related terms Alzheimer Disease, Cognitive Dysfunction
Enrollment 150 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov